News

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of …
LIBERATE-1, the first-in-human application of Vivani’s NanoPortalTM implant technology, showed a positive safety and ...
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss ...
Yahoo Finance1d
Vivani Medical, Inc. (VANI) Income Statement - Yahoo Finance
Get the detailed quarterly/annual income statement for Vivani Medical, Inc. (VANI). Find out the revenue, expenses and profit or loss over the last fiscal year.